

Supplementary Table 3. Baseline characteristics of study population after 1:1 propensity score matching

Characteristic	Total (n = 333,974)	Original valsartan (n = 166,987)	NDMA-contained valsartan (n = 166,987)	p value
Age (yr)	59.2 ± 11.8	59.2 ± 11.7	59.1 ± 11.8	0.008 ^{b)}
Sex				> 0.999
Male	186,118 (55.7)	93,059 (55.7)	93,059 (55.7)	
Female	147,856 (44.3)	73,928 (44.3)	73,928 (44.3)	
BMI (kg/m ²)	25.2 ± 3.2	25.2 ± 3.1	25.3 ± 3.3	0.002 ^{b)}
CCI				0.046
0	104,918 (31.4)	52,366 (31.4)	52,552 (31.5)	
1	91,772 (27.5)	46,017 (27.6)	45,755 (27.4)	
2	60,815 (18.2)	30,149 (18.1)	30,666 (18.4)	
≥ 3	76,469 (22.9)	38,455 (23.0)	38,014 (22.8)	
Being a prevalent user				> 0.999
No	308,628 (92.4)	154,314 (92.4)	154,314 (92.4)	
Yes	25,346 (7.6)	12,673 (7.6)	12,673 (7.6)	
Drinking status				0.005
No	177,969 (53.3)	88,577 (53.0)	89,392 (53.5)	
Yes	156,005 (46.7)	78,410 (47.0)	77,595 (46.5)	
Smoking status				0.006
Current	76,836 (23.0)	38,038 (22.8)	38,798 (23.2)	
Ever	59,463 (17.8)	29,743 (17.8)	29,720 (17.8)	
Never	197,675 (59.2)	99,206 (59.4)	98,469 (59.0)	
Disability				< 0.001
No	300,461 (90.0)	151,058 (90.5)	15,929 (9.5)	
Yes	33,513 (10.0)	149,403 (89.5)	17,584 (10.5)	
Level of healthcare provider				> 0.999
Tertiary	1,844 (0.6)	922 (0.6)	922 (0.6)	
Secondary	51,010 (15.3)	25,505 (15.3)	25,505 (15.3)	
Primary	242,030 (72.5)	121,015 (72.5)	121,015 (72.5)	
Healthcare center	37,224 (11.2)	18,612 (11.2)	18,612 (11.2)	
Others ^{a)}	1,866 (0.6)	933 (0.6)	933 (0.6)	
Follow-up duration (yr)		8.0 [0]	4.4 [2.9]	< 0.001 ^{b)}

Values are presented as mean ± standard deviation, number (%), or median [interquartile range].

NDMA, N-nitrosodimethylamine; BMI, body mass index; CCI, Charlson comorbidity index.

^{a)}Others' healthcare providers included dentistry, psychiatry, and oriental medicine.

^{b)}Welch's t-test was performed for unequal population variances.